CRDF - CIK 0001213037
Cardiff Oncology, Inc. has filed 1,000 documents with the SEC between 2012 and 2026. The most frequent type is major company event (391 filings), alongside the regular cadence of annual reports, quarterly reports, and event disclosures every public company must make. Use the filters to focus on one filing type, or flip the sort to trace the company's history from its earliest paperwork.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Filing | Type | Filed | Period covered |
|---|---|---|---|
| Major company event | 8-K | 2026-05-19 | 2026-05-19 |
| Major company event | 8-K | 2026-05-14 | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-14 | 2026-03-31 |
| Insider trade | 4 | 2026-04-28 | 2026-04-27 |
| New insider ownership | 3 | 2026-04-28 | 2026-04-27 |
| Proxy materials | DEFA14A | 2026-04-23 | - |
| Proxy statement | DEF 14A | 2026-04-23 | 2026-06-11 |
| Annual report to shareholders | ARS | 2026-04-23 | 2025-12-31 |
| Insider trade | 4 | 2026-04-16 | 2026-04-14 |
| New insider ownership | 3 | 2026-04-16 | 2026-04-06 |
| Insider trade (amended) | 4/A | 2026-04-16 | 2026-04-06 |
| Insider trade | 4 | 2026-04-16 | 2026-04-06 |
| Major company event | 8-K | 2026-04-09 | 2026-04-06 |
| Insider trade | 4 | 2026-04-02 | 2026-03-31 |
| Major company event | 8-K | 2026-04-02 | 2026-03-27 |
| SCHEDULE 13G/A | - | 2026-03-26 | - |
| Major company event | 8-K | 2026-02-25 | 2026-02-25 |
| Major company event | 8-K | 2026-02-24 | 2026-02-24 |
| Annual report | 10-K | 2026-02-24 | 2025-12-31 |
| Insider trade | 4 | 2026-02-18 | 2026-02-13 |
| Insider trade | 4 | 2026-02-18 | 2026-02-17 |
| New insider ownership | 3 | 2026-02-09 | 2026-01-27 |
| Major company event | 8-K | 2026-01-27 | 2026-01-27 |
| Major company event | 8-K | 2025-11-06 | 2025-11-06 |
| Quarterly report | 10-Q | 2025-11-06 | 2025-09-30 |
| Employee stock plan | S-8 | 2025-08-28 | - |
| SCHEDULE 13G/A | - | 2025-08-14 | - |
| Insider trade | 4 | 2025-07-31 | 2025-07-30 |
| Major company event | 8-K | 2025-07-29 | 2025-07-29 |
| Quarterly report | 10-Q | 2025-07-29 | 2025-06-30 |
| SCHEDULE 13G | - | 2025-07-29 | - |
| New insider ownership | 3 | 2025-07-08 | 2025-06-16 |
| Insider trade | 4 | 2025-06-30 | 2025-06-26 |
| Insider trade | 4 | 2025-06-30 | 2025-06-26 |
| Insider trade | 4 | 2025-06-30 | 2025-06-26 |
| Insider trade | 4 | 2025-06-27 | 2025-06-26 |
| Insider trade | 4 | 2025-06-27 | 2025-06-26 |
| Insider trade | 4 | 2025-06-27 | 2025-06-26 |
| Major company event | 8-K | 2025-06-26 | 2025-06-26 |
| Major company event | 8-K | 2025-06-17 | 2025-06-13 |
| EFFECT | - | 2025-05-13 | - |
| Company correspondence | CORRESP | 2025-05-12 | - |
| S-3/A | - | 2025-05-08 | - |
| Major company event | 8-K | 2025-05-08 | 2025-05-08 |
| Quarterly report | 10-Q | 2025-05-08 | 2025-03-31 |
| Proxy materials | DEFA14A | 2025-04-30 | - |
| Annual report to shareholders | ARS | 2025-04-29 | 2024-12-31 |
| Proxy statement | DEF 14A | 2025-04-29 | 2025-04-29 |
| SCHEDULE 13G | - | 2025-04-23 | - |
| Insider trade | 4 | 2025-03-13 | 2025-03-11 |